JPS6011430A - 腎疾患に対する治療薬 - Google Patents
腎疾患に対する治療薬Info
- Publication number
- JPS6011430A JPS6011430A JP11849283A JP11849283A JPS6011430A JP S6011430 A JPS6011430 A JP S6011430A JP 11849283 A JP11849283 A JP 11849283A JP 11849283 A JP11849283 A JP 11849283A JP S6011430 A JPS6011430 A JP S6011430A
- Authority
- JP
- Japan
- Prior art keywords
- group
- fab
- bonding
- acid
- basement membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000017169 kidney disease Diseases 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 201000001474 proteinuria Diseases 0.000 claims abstract description 11
- 206010030113 Oedema Diseases 0.000 claims abstract description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 7
- 125000000542 sulfonic acid group Chemical group 0.000 claims abstract description 6
- 208000034767 Hypoproteinaemia Diseases 0.000 claims abstract description 5
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 17
- 210000000585 glomerular basement membrane Anatomy 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000035699 permeability Effects 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract description 3
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 3
- 201000008383 nephritis Diseases 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 16
- 210000002469 basement membrane Anatomy 0.000 description 15
- 229940079593 drug Drugs 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 101800000112 Acidic peptide Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical class OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- -1 carbohydrate polysaccharides Chemical class 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 208000019411 steroid-resistant nephrotic syndrome Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11849283A JPS6011430A (ja) | 1983-06-30 | 1983-06-30 | 腎疾患に対する治療薬 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11849283A JPS6011430A (ja) | 1983-06-30 | 1983-06-30 | 腎疾患に対する治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6011430A true JPS6011430A (ja) | 1985-01-21 |
| JPH034045B2 JPH034045B2 (enrdf_load_stackoverflow) | 1991-01-22 |
Family
ID=14738007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11849283A Granted JPS6011430A (ja) | 1983-06-30 | 1983-06-30 | 腎疾患に対する治療薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6011430A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041616A (ja) * | 1983-08-12 | 1985-03-05 | Medekusu:Kk | 腎疾患に対する治療薬 |
| JPS63112994A (ja) * | 1986-10-31 | 1988-05-18 | Hajime Inamoto | モノクロ−ナル抗体を用いた尿中腎抗原の測定による腎障害の診断方法 |
| JPH06296496A (ja) * | 1993-10-27 | 1994-10-25 | Hajime Inamoto | 尿中腎抗原の測定による腎障害の診断方法に用いるモノクローナル抗体を産生するハイブリドーマ |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5899422A (ja) * | 1981-06-25 | 1983-06-13 | ザ・ボ−ド・オブ・トラステイ−ズ・オブ・ザ・レランド・スタンフオ−ド・ジユニア−・ユニバ−シテイ | 対立遺伝子特異性免疫療法のための適用形態 |
-
1983
- 1983-06-30 JP JP11849283A patent/JPS6011430A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5899422A (ja) * | 1981-06-25 | 1983-06-13 | ザ・ボ−ド・オブ・トラステイ−ズ・オブ・ザ・レランド・スタンフオ−ド・ジユニア−・ユニバ−シテイ | 対立遺伝子特異性免疫療法のための適用形態 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041616A (ja) * | 1983-08-12 | 1985-03-05 | Medekusu:Kk | 腎疾患に対する治療薬 |
| JPS63112994A (ja) * | 1986-10-31 | 1988-05-18 | Hajime Inamoto | モノクロ−ナル抗体を用いた尿中腎抗原の測定による腎障害の診断方法 |
| JPH06296496A (ja) * | 1993-10-27 | 1994-10-25 | Hajime Inamoto | 尿中腎抗原の測定による腎障害の診断方法に用いるモノクローナル抗体を産生するハイブリドーマ |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH034045B2 (enrdf_load_stackoverflow) | 1991-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoshioka et al. | Glomerular localization of type III collagen in human kidney disease | |
| JP2755395B2 (ja) | Ｈｉｖ感染細胞に殺作用する抗体異種結合体 | |
| Chan et al. | Regulation of the immune response: V. An analysis of the function of the Fc portion of antibody in suppression of an immune response with respect to interaction with components of the lymphoid system | |
| Schaapherder et al. | Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera | |
| CN101421304A (zh) | 亲和区 | |
| JPS6319561A (ja) | 抗ヒト肺癌単クロ−ン性抗体 | |
| Ran et al. | Tumor‐associated immunogolobulins. The elution of IgG2 from mouse tumors | |
| EP0585224A1 (en) | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS | |
| JP2013535444A (ja) | 注意欠陥多動性障害を治療する方法 | |
| AU2016206156A1 (en) | Method for preparing new type of recombinant anti-TNF-alpha chimeric monoclonal antibody and use | |
| CN117752684A (zh) | 一种生物正交靶向的工程化细胞药物及制备方法其应用 | |
| JP2002538170A5 (enrdf_load_stackoverflow) | ||
| DE3854267T2 (de) | HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung. | |
| JPH03503840A (ja) | 異種連結抗体およびその治療的使用 | |
| JPS6011430A (ja) | 腎疾患に対する治療薬 | |
| JPH05503098A (ja) | セプシスの処理のためのサイトカイン抗体 | |
| Saji et al. | Infliximab for Kawasaki syndrome | |
| Loutis et al. | Induction of erosive arthritis in mice after passive transfer of anti-type II collagen antibodies | |
| Lambert et al. | The interaction of Tamm-Horsfall protein with the extracellular matrix | |
| Nussenzweig et al. | C3-receptor sites on leukocytes: Possible role in opsonization and in the immune response | |
| JPH03503844A (ja) | Ｌａｋ細胞サイトトキシン | |
| EP0326148A1 (en) | Human monoclonal antibody specific for Pseudomonas aeruginosa and hybrid cell lines | |
| EP1137433B1 (en) | Pharmaceutical compositions containing protein-disulfide isomerases | |
| Suzuki et al. | Solubilization of immune complex deposits by native 7S IgG molecules in lupus glomerulonephritis--a possible antigen excess effect on rheumatoid factor-IgG complexes | |
| CA2088370C (en) | New use of monoclonal antibody |